Physician profile
Daniel Raymond Klaber
NPI 1073002465
$3,321.58
in general payments reported to CMS, 2019-2025
35 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $624 · 2023: $289 · 2024: $956 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.05 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $352.14 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $305.42 | 2022-2025 | |
| Axsome Therapeutics, INC. | $209.07 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $123.89 | 2022-2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.34 | 2024-2025 | Xifaxan, Relistor |
| Gilead Sciences, INC. | $114.82 | 2021-2025 | |
| Novo Nordisk INC | $104.31 | 2021-2025 | Wegovy |
| Astellas Pharma US INC | $95.74 | 2021-2024 | Veozah |
| Alkermes, INC. | $91.52 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Exact Sciences Corporation | $90.97 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $87.15 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $79.39 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $70.52 | 2021-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $68.69 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $66.15 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $61.44 | 2023-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $58.55 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Insulet Corporation | $57.22 | 2021-2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.20 | 2021-2025 | Caplyta |
| Pfizer INC. | $45.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $38.54 | 2021-2025 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $33.54 | 2022 | |
| Amgen INC. | $30.02 | 2022-2024 | Prolia, Evenity |
| Vanda Pharmaceuticals INC. | $29.89 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $29.78 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.58 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $28.76 | 2021 | |
| Indivior INC. | $25.29 | 2025 | Sublocade |
| Lundbeck LLC | $19.57 | 2025 | Rexulti |
| Mylan Specialty L.P. | $18.71 | 2021 | |
| Abbott Laboratories | $17.04 | 2021 | |
| Almatica Pharma LLC | $15.83 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Klaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.